Unlike in our previous case report, this patient had LOH 32.9%, despite not having any HR–DDR gene mutations, suggesting that other DDR mutations can contribute to “HRDness” and still benefit from PARP inhibition therapy, further highlighting the importance in designating HRD status in melanoma patients. The gene discussed is PARP1; the disease is melanoma.